Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn‟s disease (Ileo-Colitis)

Next Previous
X
Search
Trial Profile

A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn‟s disease (Ileo-Colitis)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mongersen (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IGON-1
  • Sponsors Nogra Pharma

    • Most Recent Events

    • 13 Jan 2016 Post-hoc analysis published in the Alimentary Pharmacology and Therapeutics.
    • 19 May 2015 Results (correlation of PRO2 with CDAI Score at week 12) presented at the Digestive Disease Week 2015.
    • 19 May 2015 Sub-group analysis data published in a Celgene Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top